Navigation Links
Chromogen in Biological Products

FAST RED Chromogen (SIGNET) from Covance Research Products, Inc

Description: Signets FAST RED Chromogen System consists of FAST RED chromogen tablets and substrate buffer. FAST RED reacts in the presence of alkaline phosphatase to produce red staining with minimal background noise. The FAST RED tablets provides enough material for 1000 tests....
Company:Covance Research Products, Inc

NBT/BCIP Chromogen System (SIGNET) from Covance Research Products, Inc

Description: SIGNETs BCIP/NBT Chromogen system consists of [5-Bromo-4-Chloro-3- Indolyl Phosphate/Nitro Blue Tetrazolium] chromogen in a single component solution. The ready-to-use BCIP/NBT solution reacts in the presence of alkaline phosphatase to produce purple staining with minimal background noise. ...
Company:Covance Research Products, Inc

NBT/BCIP Chromogen System (SIGNET) from Covance Research Products, Inc

Description: Covance's BCIP/NBT Chromogen system consists of [5-Bromo-4-Chloro-3- Indolyl Phosphate/Nitro Blue Tetrazolium] chromogen in a single component solution. The ready-to-use BCIP/NBT solution reacts in the presence of alkaline phosphatase to produce a purple staining with minimal background noise. ...
Company:Covance Research Products, Inc

FAST RED Chromogen System (SIGNET) from Covance Research Products, Inc

Description: Signets FAST RED Chromogen System consists of FAST RED chromogen tablets and substrate buffer. FAST RED reacts in the presence of alkaline phosphatase to produce red staining with minimal background noise. The FAST RED System provides enough material for 300 tests. The System Contains: ...
Company:Covance Research Products, Inc

Crystal / Mount mounting medium - general purpose from GeneTex

Description:.... Crystal/Mount can also be used on tissue sections stained with chromogens that are insoluble in organic solvents, such as the horseradish peroxidase chromogen diaminobenzidine (DAB). Tissue sections stained with DAB can be mounted immediately from water, thereby eliminating the time and reagent expense requi...
Company:GeneTex

Clarion mounting medium - DAB NBT TNBT Vega Red and Fuchsin from GeneTex

Description:...dine (DAB), Vega Red, New Fuchsin, and any other organic solvent compatible chromogen substrates on tissue sections. Clarin can be used for histology and cytolog...igin. The absence of xylene makes Clarin an excellent choice where BCIP/NBT chromogen is used, due to the great reduction in crystalline precipitation. The advan...
Company:GeneTex
Other Tags
(Date:6/18/2013)... Ph.D., Medical Research Council, Laboratory of Molecular Biology, ... 2013 ICAAC Young Investigator Award. Torrent is being ... the first algorithm to predict antimicrobial regions in ... "we are now applying this algorithm to interrogate ... peptide leads with very appealing results." , ...
(Date:6/18/2013)... June 18, 2013: The Association for Molecular Pathology is ... American Societies for Experimental Biology (FASEB) on July 1, ... on June 3, 2013. , The 26 constituent ... share a common vision for the advancement of research ... and translational research is more important now than ever," ...
(Date:6/18/2013)... a chemical modification of DNA and this modification ... DNA sequence. Until now, scientists believed that this ... genes. Today, a team of researchers from the ... Dermitzakis, Louis-Jeantet Professor at the Faculty of Medicine, ... and that DNA methylation may play both a ...
Breaking Biology News(10 mins):The American Society for Microbiology honors Marc Torrent 2The secret of DNA methylation 2
(Date:6/19/2013)... PrettySkin4Less announces it is stocking up with ... top skin care manufacturer EMINENCE to meet customer demands. ... and active organic ingredients to promote actual change rather ... products offer. For this reason it’s not hard to ... like products that do what they say they will ...
(Date:6/19/2013)... 2013 Strict rules for ... Orriant is launching a new tool to help ... with regulations. New HHS regulations will soon ... if their employer offers outcome-based, health-contingent, compliant wellness ... with these standards for nearly a decade. Orriant ...
(Date:6/19/2013)... New York, New York (PRWEB) June 19, 2013 ... involving pancreatitis and pancreatic cancer continue to mount in ... the U.S. Food & Drug Administration (FDA) recently held ... other diabetes drugs known as incretin mimetics. According ... may seek additional data from the makers of Januvia ...
(Date:6/19/2013)... In what is believed to be the largest follow-up ... hereditary dystonia a movement disorder that can cause ... report good success rates and lasting benefits. , Michele ... at Cedars-Sinai Medical Center,s Department of Neurology, and Ron ... at Beth Israel Deaconess Medical Center in Boston, published ...
(Date:6/19/2013)... disparities between minority and white clients in success ... these disparities vary widely from state to state. ... states there,s something amiss," says Stephan Arndt, Ph.D., ... strong racial and ethnic disparities for people in ... successfully, and those disparities are something we need ...
Breaking Medicine News(10 mins):Health News:PrettySkin4Less Launches New Innovative Skin Serums with Active Organic Ingredients to World Wide Consumer Base 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3
Other Contents